MOR: MorphoSys AG Net earnings per share (EPS TTM)
MorphoSys AG is optimizing its production links by eliminating dependence on external vendors. GURU.Markets quotes drive this chart, where the 12-month rolling net income per share demonstrates the growth trajectory, and -3.50 represents the current level of the metric. The business relies on the HuCAL and Ylanthia ecosystem with strong partner lock-in, while ensuring strict temperature control during drug delivery.
Analytical breakdowns for MorphoSys Inc (MOR)
- current quotes and average value forecast:
- market capitalization information:
- business book valuation details:
- debt and liquidity details:
Debt to Equity MorphoSys AG|MOR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity MorphoSys Corp|MOR - Company Aggregate Indebtedness|Debts to Book Capitalization MorphoSys AG|MOR - Company Long-Term Loans and Borrowings|Company Short-Term Debt MorphoSys|Quick Liquidity morphosys.com
- earnings and multiples data:
MOR - Net Financial Result|Future Profit MorphoSys AG|MOR - Market Cap to Earnings|Future Price to Earnings MorphoSys|MOR - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio MorphoSys AG|MOR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) MorphoSys|MOR - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth morphosys.com|MOR - Net earnings per share change in current year|Net earnings per share growth forecast for next year MorphoSys AG
Summary company analysis:MorphoSys AG (MOR)
The investment attractiveness of MorphoSys AG (MOR) is based on the efficiency of targeted antibody development and the stability of partner royalties. Net income per share (TTM) measures the portion of annual income attributable to a single security. By analyzing this 12-month net income per share chart, an investor can see the actual yield adjusted for the number of shares. A diversified pipeline minimizes the volatility of this metric, confirming the stability of the company's capital.
Competing companies
ONC - Earnings per share for the last twelve months|Earnings per share for the trailing year HALO (halozyme.com)|RVMD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Ascentage Pharma Group International (AAPG)|Earnings per share for the last twelve months CG Oncology Corp|Net earnings per share for the last 12 months UroGen Pharma Corp (URGN)|Earnings per share for the last twelve months Bicara Therapeutics Inc. (BCAX)|PSNL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Erasca ERAS|Earnings per share for the trailing year DCTH|YMAB - Earnings per share for the last twelve months|Earnings per one share for the last 12 months AURA|CADL: Net earnings per share (EPS TTM)|accuray.com - Earnings per share for the trailing year|Earnings per share for the last twelve months SELLAS Life Sciences Group, Inc.|Net earnings per one share for the last twelve months Actuate Therapeutics Inc. ACTU|Earnings per share for the last twelve months Citius Oncology, Inc (CTOR)|Net earnings per share for the last four quarters tuhurabio.com|Protara Therapeutics - Net earnings per share for the last 12 months|fatetherapeutics.com (FATE) - Net earnings per one share for the last twelve months|WHWK - Earnings per share for the last twelve months|Net earnings per share for the last four quarters TScan Therapeutics TCRX|CSBR (championsoncology.com) - Net earnings per share for the last 12 months|XBiotech - Earnings per share for the trailing year|CVM (CEL-SCI Corp.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ostherapies.com|Net earnings per share (EPS TTM) RADX|artivabio.com (ARTV) - Net earnings per share for the trailing year|Earnings per share for the last twelve months Adlai Nortye ANL|VERU - Net earnings per share for the last 12 months|TPST - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Xilio Therapeutics, Inc.|renovarobio.com (RENB) - Earnings per share for the last twelve months|Mural Oncology - Earnings per share for the trailing year|KAPA (Kairos Pharma Limited) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months OnKure (OKUR)|Net earnings per share (EPS TTM) GDTC|Net earnings per share (EPS TTM) curis.com (CRIS)|Earnings per share for the last twelve months Apollomics APLM|THAR: Earnings per share for the last 12 months|Advanced Biomed Corp - Net earnings per share (EPS TTM)|Genprex Inc (GNPX) - Net earnings per share for the last 12 months|CLDI: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Sunshine Biopharma Inc. (SBFM)|Earnings per share for the last twelve months Xenetic Biosciences Inc.|SLRX: Earnings per share for the trailing year|Net earnings per share for the last 12 months PPBT (Purple Biotech Corp)|AONC (aoncology.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) BGNE (BeiGene, Ltd.)|CKPT - Net earnings per share for the last 12 months|ELEV: Net earnings per share for the last 12 months|ICAD - Net earnings per share (EPS TTM)|ikenaoncology.com (IKNA) - Earnings per share for the last twelve months|Notable Labs Corp - Earnings per share for the trailing year|VIRX (Viracta Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months nayabiosciences.com NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
